a Pharmacology Department, Center for Evaluation and Information on Pharmacodependence (CEIP) , Nantes University Hospital , Nantes , France.
J Addict Dis. 2014;33(1):15-23. doi: 10.1080/10550887.2014.882725.
In 2004, the health authorities (French National Agency for Medicines and Health Products Safety-ANSM) modified the summary of zolpidem characteristics. Particularly it now includes the sentence "a pharmacodependence may materialize." The current article aims to show that despite this modification, zolpidem continues to be associated with problematic drug use, as the official system (Center for Evaluation and Information on Pharmacodependence-Addictovigilance network) providing information on the abuse and dependence potential of drugs informs us. The authors reviewed the literature on this topic and analyzed French data from zolpidem's postmarketing period that were collected by the Addictovigilance network from 2003 to 2010. Postmarketing data and the 30 case reports yielded from the literature review highlight a significant dependence and abuse potential for zolpidem. This survey led to propose in stronger additional rules in France to try to mitigate the abuse potential of zolpidem.
2004 年，卫生当局（法国国家药品和保健产品安全署-ANSM）修改了唑吡坦特性摘要。特别指出，现在包括“可能出现药物依赖”这句话。本文旨在表明，尽管进行了这种修改，唑吡坦仍与药物使用问题有关，因为提供有关药物滥用和依赖潜力信息的官方系统（药物评估和信息中心-成瘾监测网络）向我们报告了这一点。作者回顾了关于这个主题的文献，并分析了 2003 年至 2010 年期间成瘾监测网络从唑吡坦上市后时期收集的法国数据。上市后数据和文献综述中的 30 份案例报告突出了唑吡坦具有显著的依赖和滥用潜力。这项调查促使法国提出更严格的附加规则，试图减轻唑吡坦的滥用潜力。
